KẾT QUẢ HÓA TRỊ BỔ TRỢ PHÁC ĐỒ XELOX Ở BỆNH NHÂN UNG THƯ DẠ DÀY TẠI BỆNH VIỆN TRUNG ƯƠNG THÁI NGUYÊN

Abstract

Objectives: Evaluating the results of adjuvant chemotherapy with XELOX regimen in gastric cancer patients at Thai Nguyen General hospital period 2021 – 2024. Methods: Cross-sectional descriptive study on 27 patients diagnosed with stage II - III gastric cancer receiving adjuvant chemotherapy with XELOX regimen at the Oncology Center - Thai Nguyen General Hospital from 03/2021 to 03/2024. Results: The male/female ratio is 2/1, the average age of disease is 62.63 ± 6.06 months. 51.85% of patients had less than 16 lymph nodes removed. Poorly differentiated adenocarcinoma accounts for the most with 55.56%. The main tumor stage is T4a, accounting for 40.74%, N1 lymph node metastasis accounts for the highest rate at 40.74%, and the most common disease stage is stage IIA, accounting for 37.04%. The overall survival and disease-free survival rates at 1 year were 88.89% and 70.07%. The overall survival and disease-free survival rates of 13 patients followed for 24 months were 92.31% and 69.23%, respectively. Conclusion: Gastric cancer is often detected when the tumor is large and has metastasized to lymph nodes. In our study, Adjuvant chemotherapy with XELOX regimen helped achieve overall survival and disease-free survival.